Health and Healthcare
Myriad's Alarming Alzheimer's Forecasts
Published:
Last Updated:
Myriad Genetics, Inc. (MYGN-NASDAQ) has issued a press release discussing a new study showing that the potential savings to the US healthcare system alone could be $4.0 Trillion from 2010 to 2050. It estimates that in 2030 the rate from today’s 5.1 million Americans with Alzheimer’s will grow to 7.7 million and then to 16 million by 2050.
What Myriad is doing is essentially promoting its Flurizan (currently in Phase II’s) and it is trying to speed things up by noting that the delay of even a year could have tremendous expense ramifications. We noted many of the other company names working in the sector after Barron’s ran a cover story on this epidemic that Barron’s left off.
These current numbers and projections are seeming to get worse and worse each year
Jon C. Ogg
May 15, 2007
Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.
Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
